# US 8,569,372 B2 · Method for preventing or treating a disease, disorder or condition induced by retina ischemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,372 B2
- Document ID: US8569372B2
- Status: Granted
- Kind: B2
- Application number: 13/246,057
- Filed: 2011-09-27
- Published: 2013-03-28
- Granted: 2013-10-29
- Earliest claimed: 2011-09-27
- Assignees: Hsiao-Ming Chao; Chieh-Cheng Ke
- Applicants: Hsiao-Ming Chao
- Inventors: Hsiao-Ming Chao
- Web page: https://patentgrep.com/patent/US8569372B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for preventing or treating a disease, disorder or condition induced by retina ischemia, comprising administering to a subject in need thereof a S-allyl-L-cysteine in a therapeutically effective amount.

## Claims

### Claim 1

A method for treating retina ischemia in a subject in need thereof, comprising administering to the subject a S-allyl-L-cysteine in a therapeutically effective amount, wherein the S-allyl-L-cysteine acts as an antioxidant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine attenuates the retina ischaemia induced reduction in electroretinogram b-wave amplitude.

### Claim 3 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine attenuates the retina ischemia induced decrease in Thy-1 mRNA indexing retinal ganglion cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine attenuates HIF-1 Alpha mRNA increase induced by the retina ischemia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine attenuates VEGF mRNA increase induced by the retina ischemia.

### Claim 6 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine attenuates MMP-9 mRNA increase induced by the retina ischemia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the S-allyl-L-cysteine protects retinal ganglion cell-5 against oxidative stress.

### Claim 8 (depends on 7)

The method of claim 7, wherein the oxidative stress is induced by H2O2.